LeMaitre Vascular, Inc. $LMAT Stock Holdings Increased by Vest Financial LLC

Vest Financial LLC grew its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 10.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 85,152 shares of the medical instruments supplier’s stock after buying an additional 8,290 shares during the period. Vest Financial LLC owned 0.37% of LeMaitre Vascular worth $7,033,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in the business. Kings Path Partners LLC acquired a new stake in shares of LeMaitre Vascular during the 3rd quarter worth about $386,000. Copeland Capital Management LLC boosted its holdings in LeMaitre Vascular by 10.1% in the third quarter. Copeland Capital Management LLC now owns 924,081 shares of the medical instruments supplier’s stock valued at $76,320,000 after purchasing an additional 84,618 shares in the last quarter. Tidal Investments LLC acquired a new position in LeMaitre Vascular in the second quarter valued at approximately $526,000. Engineers Gate Manager LP boosted its holdings in LeMaitre Vascular by 38.4% in the second quarter. Engineers Gate Manager LP now owns 14,008 shares of the medical instruments supplier’s stock valued at $1,344,000 after purchasing an additional 3,888 shares in the last quarter. Finally, Nykredit A S purchased a new position in LeMaitre Vascular in the second quarter valued at approximately $82,000. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Price Performance

LMAT stock opened at $85.33 on Friday. The company has a market capitalization of $1.95 billion, a P/E ratio of 30.76, a PEG ratio of 2.41 and a beta of 0.48. LeMaitre Vascular, Inc. has a twelve month low of $78.22 and a twelve month high of $118.01. The business has a 50 day simple moving average of $81.03 and a 200-day simple moving average of $93.41. The company has a current ratio of 16.31, a quick ratio of 13.96 and a debt-to-equity ratio of 0.40.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business had revenue of $70.38 million during the quarter, compared to analyst estimates of $71.47 million. During the same period in the previous year, the firm earned $0.60 earnings per share. The business’s revenue was up 9.6% compared to the same quarter last year. As a group, equities analysts anticipate that LeMaitre Vascular, Inc. will post 2.89 EPS for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 3rd. Investors of record on Thursday, August 20th were issued a dividend of $0.25 per share. The ex-dividend date of this dividend was Thursday, August 20th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.2%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 35.09%.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Wells Fargo & Company dropped their target price on shares of LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 5th. Weiss Ratings upgraded shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Finally, Zacks Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Four equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, LeMaitre Vascular has an average rating of “Hold” and a consensus price target of $110.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.